Infection Susceptibility Risk Assessments for Complement Inhibitors

Complement inhibitors are molecular targeted therapies designed to suppress the overactivation of the complement system. They have demonstrated efficacy in treating refractory diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), and IgA nephropathy. Representative agents include eculizumab, ravulizumab, and pegcetacoplan.
However, since the complement pathway plays a critical role in host defense against infections, its inhibition is associated with an increased risk of serious infections, including meningitis. Consequently, vaccination is currently mandatory for patients undergoing treatment with complement inhibitors.
That said, certain modalities of complement inhibitors exhibit a comparatively lower risk of infection, providing a potential advantage in infection risk management over other therapies.
FUJIFILM Toyama Chemical leverages its long-standing expertise in antibiotic drug discovery to offer drug discovery support services based on a robust research platform. Among these services, we provide infection susceptibility risk assessments for complement inhibitors to support your drug development efforts.